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Background
Oxaliplatin is a platinum based agent that is a antineoplas-
tic used in colorectal carcinoma in combination with
flourouracil and leucovorin. A 45 year old female patient
developed anaphylaxis on prior 2 cycles to this platinum
agent with dyspnea and hypotension on the latter cycle.
Further cycles were stopped and an allergist consult was
obtained.
Method
In this case a premedication protocol of dexamethasone
10 mg + diphenhydramine 50 mg + famotidine 20 mg by
mouth were administered 13 hours, 6 hours and 1 hour
respectively prior to the infusion of 40 mg of oxaliplatin
in 1:10000, 1:1000, 1:100, 1:10 graded dilutions. Each
dilution was infused over 1 hour under close telemetry
monitoring. A final dilution that contained 90 % of the
dose was infused over 4 hours until completion.
Results
The patient tolerated the desensitization protocol well
with the premedication of dexamethasone+diphenhydra-
mine+famotidine. The graded dilutional desensitization
approach allowed the patient to achieve tolerance to the
drug without any significant adverse events and was able
to continue her cycles of antineoplastic regimen.
Conclusions
This graded desensitization protocol permits the continua-
tion of antineoplastic treatment protocols in patients that
may have a varying degrees of hypersensitivity to oxalipla-
tin agents.
A premedicated patient in addition to a graded drug
dilution approach may allow administration of this poten-
tial life saving drug. The patient must at all times during
the protocol be closely monitored for any treatment
adjustments for tolerability.
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